Allylestrenol

产品说明书

Print
Chemical Structure| 432-60-0 同义名 : 烯丙雌醇
CAS号 : 432-60-0
货号 : A810685
分子式 : C21H32O
纯度 : 97%
分子量 : 300.478
MDL号 : MFCD00198957
存储条件：

Pure form Sealed in dry,Room Temperature

In solvent -20°C:3-6个月-80°C:12个月
溶解度 : -
动物实验配方：
生物活性
描述 Allylestrenol is a synthetic steroidal progestin that is used to prevent recurrent pregnancy loss, threatened miscarriage, and premature labor. Allylestrenol combined with ritodrine can significantly reduce the expression levels of IL-17, IL-10 and IL-6 in TPTL (threatened premature labor), reduce adverse pregnancy conditions, prolong gestational weeks, and has higher safety and better application value[3]. Allylestrenol is useful for treatment of urinary disturbances caused by prostatic hypertrophy[4]. Allylestrenol is an effective and safe medical treatment for patients with symptomatic BPH(benign prostatic hypertrophy). Hormonal and histopathologic findings suggest that the prostate gland may regrow after discontinuation of medication[5].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.33mL

0.67mL

0.33mL

16.64mL

3.33mL

1.66mL

33.28mL

6.66mL

3.33mL
参考文献

[1]Saure A, Karjalainen O, et al. The effect of synthetic gestagens on progesterone formation in vitro in human corpus luteum of early pregnancy. Eur J Obstet Gynecol Reprod Biol. 1976;6(4):223-34.

[2]Saure A, Teravainen T, et al. The effect of synthetic gestagens on progesterone formation in vitro in human placenta of early pregnancy. J Reprod Fertil. 1977 Nov;51(2):369-73.

[3]Li Q, Li C, Jin H. Efficacy of allylestrenol combined with ritodrine on threatened premature labor and its influence on inflammatory factors in peripheral blood. Exp Ther Med. 2020 Feb;19(2):907-912

[4]Kohri K, Kurita T, Iguchi M, Kataoka K. [Clinical effects of allylestrenol on prostatic hypertrophy]. Hinyokika Kiyo. 1986 Mar;32(3):486-92. Japanese

[5]Noguchi K, Harada M, Masuda M, Takeda M, Kinoshita Y, Fukushima S, Miyai K, Fukuoka H, Hosaka M. Clinical significance of interruption of therapy with allylestrenol in patients with benign prostatic hypertrophy. Int J Urol. 1998 Sep;5(5):466-70